Garg Pushkal 4

4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Mar 4, 2026

Insider Transaction Report

Form 4

Period: 2026-03-02

ALNYLAM PHARMACEUTICALS, INC.ALNY

Garg Pushkal

EVP Chief R&D

Transactions

Award
Common Stock
[F1]
2026-03-02+4,769→ 26,898 total
Sale
Common Stock
[F2][F3]
2026-03-02$323.62/sh−50$16,181→ 26,848 total
Sale
Common Stock
[F2][F4]
2026-03-02$324.65/sh−97$31,491→ 26,751 total
Sale
Common Stock
[F2][F5]
2026-03-02$325.63/sh−277$90,200→ 26,474 total
Sale
Common Stock
[F2][F6]
2026-03-02$326.81/sh−421$137,587→ 26,053 total
Sale
Common Stock
[F2][F7]
2026-03-02$327.67/sh−353$115,668→ 25,700 total
Sale
Common Stock
[F2][F8]
2026-03-02$328.71/sh−107$35,172→ 25,593 total
Sale
Common Stock
[F2][F9]
2026-03-02$329.71/sh−182$60,007→ 25,411 total
Sale
Common Stock
[F2][F10]
2026-03-02$330.85/sh−87$28,784→ 25,324 total
Sale
Common Stock
[F2][F11]
2026-03-02$331.93/sh−101$33,525→ 25,223 total
Sale
Common Stock
[F2][F12]
2026-03-02$332.64/sh−42$13,971→ 25,181 total
Sale
Common Stock
[F13][F14]
2026-03-03$316.74/sh−355$112,443→ 24,826 total
Sale
Common Stock
[F13][F15]
2026-03-03$319.06/sh−317$101,142→ 24,509 total
Sale
Common Stock
[F13][F16]
2026-03-03$320.48/sh−640$205,107→ 23,869 total
Sale
Common Stock
[F13][F17]
2026-03-03$321.50/sh−463$148,855→ 23,406 total
Award
Stock Option (right to buy)
[F20]
2026-03-02+10,480→ 10,480 total
Exercise: $325.07Exp: 2036-03-02→ Common Stock (10,480 underlying)

Holdings

Common Stock
[F18]
(indirect: by Managed Account)
431
Common Stock
[F19]
(indirect: By Trust)
250

Footnotes (20)

[F1]These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
[F10]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F11]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F12]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F13]This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025.
[F14]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.45 to $317.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F15]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.71 to $319.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F16]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.97 to $320.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F17]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.30 to $321.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F18]Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
[F19]Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
[F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations.
[F20]The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
[F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F7]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F8]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F9]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Signature

By: Brett Budzinski, Attorney-in-Fact For: Pushkal Garg|2026-03-04

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT